These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27099170)

  • 1. Multiple paradoxical adverse events in a patient with ankylosing spondylitis treated with adalimumab.
    Toussirot É; Charollais R; Aubin F
    Eur J Dermatol; 2016 Aug; 26(4):406-8. PubMed ID: 27099170
    [No Abstract]   [Full Text] [Related]  

  • 2. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.
    Delobeau M; Abdou A; Puzenat E; Deveza E; Biver-Dalle C; van de Laak A; Roche-Kubler B; Vuitton L; Koch S; Wendling D; Aubin F
    J Dermatolog Treat; 2016; 27(3):251-3. PubMed ID: 26368546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed Drug Eruption to Biologics and Role of Lesional Patch Testing.
    Li PH; Watts TJ; Chung HY; Lau CS
    J Allergy Clin Immunol Pract; 2019; 7(7):2398-2399. PubMed ID: 31326380
    [No Abstract]   [Full Text] [Related]  

  • 4. Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases.
    Faivre C; Villani AP; Aubin F; Lipsker D; Bottaro M; Cohen JD; Durupt F; Jeudy G; Sbidian E; Toussirot E; Badot V; Barbarot S; Debarbieux S; Delaporte E; Goegebeur G; Morel J; Nassif A; Duru G; Jullien D;
    J Am Acad Dermatol; 2016 Jun; 74(6):1153-9. PubMed ID: 26965410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sweet's syndrome in a patient affected by ankylosing spondylitis and ulcerative colitis under treatment with adalimumab.
    Bruscino N; Grandi V; Gunnella S; Maio V
    J Eur Acad Dermatol Venereol; 2016 Jan; 30(1):195-6. PubMed ID: 25201185
    [No Abstract]   [Full Text] [Related]  

  • 6. Psoriasiform Eruption Secondary to the Use of Adalimumab.
    Esteves PM; Barbalho MG; Cortes JG; Cuzzi T; Sodre CT; Ramos-e-Silva M
    J Drugs Dermatol; 2015 Oct; 14(10):1152-4. PubMed ID: 26461828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transaminase elevation secondary to the use of adalimumab.
    Juan-Guardela ML; Marín-Carrillo LF; Kattah-Martínez LX; Fernández-Ávila DG
    Reumatol Clin; 2014; 10(4):265-6. PubMed ID: 24485042
    [No Abstract]   [Full Text] [Related]  

  • 8. Multiple paradoxical adverse events in a patient affected with ankylosing spondylitis treated with TNF blockers.
    Lo Nigro A; Ramonda R; Alaibac M; Modesti V; Punzi L
    Eur J Dermatol; 2011; 21(2):263-4. PubMed ID: 21411412
    [No Abstract]   [Full Text] [Related]  

  • 9. Palmoplantar pustular psoriasis induced by adalimumab: a case report and literature review.
    Ibis N; Hocaoglu S; Cebicci MA; Sutbeyaz ST; Calis HT
    Immunotherapy; 2015; 7(7):717-20. PubMed ID: 26250408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psoriasiform skin eruption in a patient receiving certolizumab-pegol for ankylosing spondylitis: Report of a case and review of the literature.
    Babuna Kobaner G; Polat Ekinci A; Yilmaz Z; Copur S
    Dermatol Ther; 2018 Sep; 31(5):e12693. PubMed ID: 30225952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mania induced by adalimumab in a patient with ankylosing spondylitis.
    Ghossoub E; Habli M; Uthman I; Maalouf FT
    Int J Psychiatry Med; 2016 Aug; 51(6):486-493. PubMed ID: 28629289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs.
    Burzi L; Repetto F; Ribero S; Mastorino L; Quaglino P; Dapavo P
    Dermatol Ther; 2022 Dec; 35(12):e15866. PubMed ID: 36175129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leucocytoclastic vasculitis associated with golimumab.
    Pàmies A; Castro S; Poveda MJ; Fontova R
    Rheumatology (Oxford); 2013 Oct; 52(10):1921-3. PubMed ID: 23530254
    [No Abstract]   [Full Text] [Related]  

  • 14. [Cutaneous lesions in a woman treated with adalimumab].
    Barreau M; Pontoizeau J; Courtheoux F; Comoz F; Leport Y; Verneuil L; Dompmartin A
    Rev Med Interne; 2015 Dec; 36(12):862-4. PubMed ID: 26003376
    [No Abstract]   [Full Text] [Related]  

  • 15. Exacerbation of infliximab-induced palmoplantar psoriasis under ustekinumab therapy in a patient with ankylosing spondylitis.
    Safa G; Martin A; Darrieux L
    J Clin Rheumatol; 2011 Oct; 17(7):385-6. PubMed ID: 21946468
    [No Abstract]   [Full Text] [Related]  

  • 16. Synovial Leishmaniasis.
    Guidelli GM; De Stefano R; Galeazzi M; Selvi E
    Arthritis Rheumatol; 2016 Apr; 68(4):931. PubMed ID: 26663894
    [No Abstract]   [Full Text] [Related]  

  • 17. Two paradoxical reactions in a patient with psoriasis and psoriatic arthritis: Adalimumab-induced hidradenitis suppurativa and secukinumab-induced alopecia areata.
    Öğüt ND
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):e468-e469. PubMed ID: 36151938
    [No Abstract]   [Full Text] [Related]  

  • 18. Infliximab-induced palmoplantar psoriasis in a patient with ankylosing spondylitis.
    Capkin E; Karkucak M; Yayli S; Aydin Çapkin A; Tosun M
    J Clin Rheumatol; 2011 Aug; 17(5):293-4. PubMed ID: 21808187
    [No Abstract]   [Full Text] [Related]  

  • 19. Morphea associated with the use of adalimumab: a case report and review of the literature.
    Ramírez J; Hernández MV; Galve J; Cañete JD; Sanmartí R
    Mod Rheumatol; 2012 Aug; 22(4):602-4. PubMed ID: 22095405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNF-α inhibitor-induced paradoxical psoriasis and erythema nodosum in a patient with ankylosing spondylitis.
    Watabe D; Amano H
    Eur J Dermatol; 2021 Jun; 31(3):412-413. PubMed ID: 34309528
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.